Structure-activity relationships in the δ-opioid receptor

Pain Reviews

Volumn 4, Issue 2, 1997, Pages 100-121

  Befort, Katia ^a   Kieffer, Brigitte L ^a,b  

^a Lab Recepteurs Proteines M   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; RECEPTOR SUBTYPE;

BINDING SITE; HUMAN; HUMAN CELL; MOLECULAR CLONING; OPIATE ADDICTION; POLYMERASE CHAIN REACTION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0030877148     PISSN: 09681302     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Browstein M. A brief history of opiates, opioid peptides and opioid receptors. Proc Natl Acad Sci USA 1993; 90: 5391-93.
2. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 1973; 179: 1011-14.
3. 3H]etorphine to rat brain homogenate. Proc Natl Acad Sci USA 1973; 70: 1947-49.
4. Terenius L. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex. Acta Pharmacol Toxicol 1973; 32: 317-19.
5. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JJ. Endogenous opioids: biology and function. Annu Rev Neurosci 1984; 7: 223-55.
6. Dickenson AH. Mechanisms of the analgesic action of opiates and opioids. Br Med Bull 1991; 47: 690-702.
7. Olson GA, Olson RD, Kastin AJ. Endogenous opiates: 1993. Peptides 1994; 15: 1513-56.
8. Rees DC, Hunter JC. Opioid receptors. In: Emmet JC ed. Comprehensive medicinal chemistry. New York: Pergamon Press, 1990: 805-46.
9. Kieffer BL. Molecular aspects of opioid receptors. In: Dickenson A, Besson JM, eds. Pain (Handbook of experimental pharmacology, vol. 130). Berlin: Springer-Verlag, 1997: 281-303.
10. Aruffo A, Seed B. Molecular cloning of a CD28 cDNA by a high-efficiency COS cells expression system. Proc Natl Acad Sci USA 1987; 84: 8573-77.
11. Evans CJ, Keith DE, Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science 1992; 258: 1952-55.
12. Kieffer BL, Befort K, Gavériaux-Ruff C, Hirth CG. The δ-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 1992; 89: 12048-52.
13. Yasuda K, Raynor K, Kong H et al. Cloning and functional comparision of κ and δ opioid receptors from mouse brain. Proc Natl Acad Sci USA 1993; 90: 6736-40.
14. Bzdega T, Chin H, Kim H, Jung HH, Kozak CA, Klee WA. Regional expression and chromosomal localization of the δ opiate receptor gene. Proc Natl Acad Sci USA 1993; 90: 9305-309.
15. Sedqi M, Roy S, Ramakrishnan S, Loh H. Expression cloning of a full length cDNA encoding delta opioid receptor from mouse thymocytes. J Neuroimmunol 1996; 65: 167-70.
16. Fukuda K, Kato S, Mori K, Nishi M, Takeshima H. Primary structures and expression from cDNAs of rat opioid receptor δ- and λ-subtypes. FEBS Lett 1993; 327: 311-14.
17. Abood ME, Noel MA, Farnsworth JS, Tao Q. Molecular cloning and expression of a δ-opioid receptor from rat brain. J Neurosci Res 1994; 37: 714-19.
18. Simonin F, Befort K, Gavériaux-Ruff C et al. The human delta opioid receptor: genomic organization, cDNA cloning, functional expression and distribution in human brain. Mol Pharmacol 1994; 46: 1015-21.
19. Knapp RJ, Malatynska E, Fang L et al. Identification of a human delta opioid receptor: cloning and expression. Life Sci 1994; 54: 463-69.
20. Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR. Human mu opiate receptor - cDNA and genomic clones: pharmacologic characterization and chromosomal assignment. FEBS Lett 1994; 338: 217-22.
21. Simonin F, Gavériaux-Ruff C, Befort K et al. Kappa opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology and expression pattern in the central nervous system. Proc Natl Acad Sci USA 1995; 92: 7006-10.
22. Li X, Keith DE, Evans CJ. Multiple opioid receptor-like genes are identified in diverse vertebrate phyla. FEBS Lett 1996; 397: 25-29.
23. Meunier J-C, Mollereau C, Toll L et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995; 377: 532-35.
24. Reinscheid RK, Nothacker H-P, Bourson A et al. Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 1995; 270: 792-94.
25. Probst WC, Snyder LA, Schuster DI, Brosius J, Sealfon SC. Sequence alignment of the G-protein-coupled receptor superfamily. DNA Cell Biol 1992; 11: 1-20.
26. Kieffer BL. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol 1995; 15: 615-35.
27. Raynor K, Kong H, Chen Y et al. Pharmacological characterization of the cloned κ-, δ- and μ-opioid receptors. Mol Pharmacol 1993; 45: 330-34.
28. Satoh M, Minami M. Molecular pharmacology of the opioid receptors. Pharmacol Ther 1995; 68: 343-64.
29. Knapp RJ, Santoro G, De Leon IA et al. Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors. J Pharmacol Exp Ther 1996; 277: 1284-91.
30. + channel: expression cloning and molecular properties. Proc Natl Acad Sci USA 1993; 90: 10235-39.
31. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Pharmacol 1993; 16: 1-18.
32. Traynor JR, Elliot J. δ-opioid receptor subtypes and cross talk with μ-receptors. Trends Pharmacol Sci 1993; 14: 84-85.
33. Traynor J. Subtypes of the κ-opioid receptor: fact or fiction? Trends Pharmacol Sci 1989; 10: 52-53.
34. Law PY, Mcginn TM, Wick MJ, Erickson LJ, Evans CJ, Loh HH. Analysis of delta-opioid receptor activities stably expressed in CHO cell lines: function of receptor density? J Pharmacol Exp Ther 1994; 271: 1686-94.
35. Bilsky EJ, Bernstein RN, Pasternak GW et al. Selective inhibition of [D-Ala2, Glu4] deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodesoxynucleotide to an opioid delta receptor. Life Sci 1994; 55: 37-43.
36. 2-agonist antinociception. NeuroReport 1994; 5: 1049-52.
37. Zaki PA, Bilsky EJ, Vanderah TW, Lai J, Evans CJ, Porreca F. Opioid receptor types and subtypes: the 8 receptor as a model. Annu Rev Pharmacol Toxicol 1996; 36: 379-401.
38. Kong HY, Raynor K, Yano H, Takeda J, Bell GI, Reisine T. Agonists and antagonists bind to different domains of the cloned kappa opioid receptor. Proc Natl Acad Sci USA 1994; 91: 8042-46.
39. Wang JB, Johnson PS, Wu JM, Wang WF, Uhl GR. Human kappa opiate receptor second extracellular loop elevates dynorphin's affinity for human mu/kappa chimeras. J Biol Chem 1994; 269: 25966-69.
40. Xue JC, Chen CG, Zhu JM et al. Differential binding domains of peptide and non-peptide ligands in the cloned rat kappa opioid receptor. J Biol Chem 1994; 269: 30195-99.
41. Fukuda K, Kato S, Mori K. Location of regions of the opioid receptor involved in selective agonist binding. J Biol Chem 1995; 270: 6702-709.
42. Hjorth SA, Thirstrup K, Grandy DK, Schwartz TW. Analysis of selective binding epitopes for the κ-opioid receptor antagonist nor-binaltorphimine. Mol Pharmacol 1995; 47: 1089-94.
43. Meng F, Hoversten MT, Thompson RC, Taylor L, Watson SJ, Akil H. A chimeric study of the molecular basis of affinity and selectivity of the K and the δ opioid receptors: potential role of extracellular domains. J Biol Chem 1995; 270: 12730-36.
44. Minami M, Onogi T, Nakagawa T et al. DAMGO, a μ-opioid receptor selective ligand, distinguishes between μ-and κ-opioid receptors at a different region from that for the distinction between μ- and δ-opioid receptors. FEBS Lett 1995; 364: 23-27.
45. Onogi T, Minami M, Katao Y et al. DAMGO, a μ-opioid receptor selective agonist, distinguishes between μ- and δ-opioid receptors around their first extracellular loops. FEBS Lett 1995; 357: 93-97.
46. Wang WW, Shahrestanifar M, Jin J, Howells RD. Studies on μ and δ opioid receptor selectivity utilizing chimeric and site-mutagenezed receptors. Proc Natl Acad Sci USA 1995; 92: 12436-40.
47. Watson B, Meng F, Thompson RC, Akil H. Structural studies of the mu opioid receptor using chimeric constructs. Analgesia 1995; 1: 825-28.
48. Xue JC, Chen C, Zhu J et al. The third extracellular loop of the μ-opioid receptor is important for agonist selectivity. J Biol Chem 1995; 270: 12977-79.
49. Claude PA, Wotta DR, Zhang XH et al. Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists. Proc Natl Acad Sci USA 1996; 93: 5715-19.
50. Li X, Varga EV, Stropova D et al. δ-opioid receptor: the third extracellular loop determines naltrindole selectivity. Eur J Pharmacol 1996; 300: R1-R2.
51. Hjorth SA, Thirstrup K, Schwartz TW. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the κ-opioid receptor. Mol Pharmacol 1996; 50: 977-84.
52. Meng F, Ueda Y, Hoversten MT et al. Mapping the receptor domains critical for the binding selectivity of δ-opioid receptor ligands. Eur J Pharmacol 1996; 311: 285-92.
53. Pepin M-C, Yue SY, Roberts E, Wahlestedt C, Walker P. Novel 'restoration of function' mutagenesis strategy to identify amino acids of the δ-opioid receptor involved in ligand binding. J Biol Chem 1997; 272: 9260-67.
54. Shahrestanifar M, Wang WW, Howells RD. Studies on inhibition of μ and δ opioid receptor binding by dithiothreitol and N-ethylmaleimide: His223 is critical for μ opioid receptor binding and inactivation by N-ethylmaleimide. J Biol Chem 1996; 271: 5505-12.
55. Valiquette M, Vu HK, Yue SY, Wahlestedt C, Walker P. Involvement of Trp-284, Val-296, and Val-297 of the human δ-opioid receptor in binding of δ-selective ligands. J Biol Chem 1996; 271: 18789-96.
56. Zhu J, Xue J-C, Law P-Y et al. The region in the μ opioid receptor conferring selectivity for sufentanil over the δ receptor is different from that over the κ receptor. FEBS Lett 1996; 384: 198-202.
57. Zhu J, Yin J, Law P-Y et al. Irreversible binding of cis-(+)-3-methylfentanyl isothiocyanate to the δ opioid receptor and determination of its binding domain. J Biol Chem 1996; 271: 1430-34.
58. Watson B, Meng F, Akil H. A chimeric analysis of the opioid receptor domains critical for the binding selectivity of μ opioid ligands. Neurobiol Dis 1996; 3: 87-96.
59. Varga EV, Li X, Stropova D et al. The third extracellular loop of the human δ-opioid receptor determines the selectivity of δ-opioid agonists. Mol Pharmacol 1996; 50: 1619-24.
60. Van Rhee AM, Jacobson KA. Molecular architecture of G protein-coupled receptors. Drug Dev Res 1996; 37: 1-38.
61. Surratt CK, Johnson PS, Moriwaki A et al. Mu opiate receptor: charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J Biol Chem 1994; 269: 20548-53.
62. Fukuda K, Terasako K, Kato S, Mori K. Identification of the amino acid residues involved in selective agonist binding in the first extracellular loop of the δ- and μ-opioid receptors. FEBS Lett. 1995; 373: 177-81.
63. Metzger TG, Ferguson DM. On the role of extracellular loops of opioid receptors in conferring ligand selectivity. FEBS Lett 1995; 375: 1-4.
64. Baldwin JM. Structure and function of receptors coupled to G proteins. Curr Opin Cell Biol 1994; 6: 180-90.
65. Schwartz TW. Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 1994; 5: 434-44.
66. Strader CD, Fong TM, Graziano MP, Tota MR. The family of G-protein-coupled receptors. FASEB J 1995; 9: 745-54.
67. Knapp RJ, Malatynska E, Collins N et al. Molecular biology and pharmacology of cloned opioid receptors. FASEB J 1995; 9: 516-25.
68. Alkorta I, Loew GH. A 3D model of the δ opioid receptor and ligand-receptor complexes. Protein Eng 1996; 9: 573-83.
69. Habibi-Nezhad B, Hanifian M, Mahmoudian M. Computer-aided receptor modelling of human opioid receptors: (mu, kappa, and delta). J Mol Med 1996; 2: 362-69.
70. Barnard EA. Pipe dreams realized. Curr Biol 1993; 3: 211-14.
71. Kong H, Raynor K, Yasuda K et al. A single residue, aspartic acid 95, in the δ-opioid receptor specifies selective high affinity agonist binding. J Biol Chem 1993; 31: 23055-58.
72. Befort K, Tabbara L, Bausch S, Chavkin C, Evans C, Kieffer BL. The conserved aspartate residue in the third putative transmembrane domain of the δ-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Mol Pharmacol 1996; 49: 216-23.
73. Strader CD, Gaffney Y, Sugg EE et al. Allele-specific activation of genetically engineered receptors. J Biol Chem 1991; 266: 5-8.
74. Befort K, Tabbara L, Kling D, Maigret B, Kieffer BL. Role of transmembrane residues of the δ-opioid receptor in ligand recognition. J Biol Chem 1996; 271: 10161-68.
75. Mansour A, Taylor LP, Fine JL et al. Key residues defining the μ-opioid receptor binding pocket: a site-directed mutagenesis study. J Neurochem 1997; 68: 344-53.
76. Cox BM. Opioid receptor-G protein interactions: acute and chronic effects of opioids. In: Herz A ed. Opioids I. (Handbook of experimental pharmacology, vol. 104/I.) Berlin: Springer-Verlag, 1993: 145-80.
77. Childers SR. Opioid receptor-coupled second messenger systems. In: Herz A ed. Opioids I. (Handbook of experimental pharmacology, vol. 104/I.) Berlin: Springer-Verlag, 1993: 189-208.
78. North RA. Opioid action on membrane ion channels. In: Herz A ed. Opioids I. (Handbook of experimental pharmacology, vol. 104/I.) Berlin: Springer-Verlag, 1993: 773-93.
79. Miyamae T, Fukushima N, Misu Y, Ueda H. δ opioid receptor mediates phospholipase C activation via Gi in Xenopus oocytes. FEBS Lett 1993; 333: 311-14.
80. Malatynska E, Wang Y, Knapp RJ et al. Human δ opioid receptor: a stable cell line for functional studies of opioids. Mol Neurosci 1995; 6: 613-16.
81. 2+ channels in GH3 cells by cloned μ- and δ-opioid receptors. Mol Pharmacol 1996; 50: 947-56.
82. Sharp BM, Shahabi NA, Heagy W et al. Dual signal transduction through opioid receptors in a transfected human T-cell line. Proc Natl Acad Sci USA 1996; 93: 8294-99.
83. Prather PL, McGinn TM, Erickson LJ, Evans CJ, Loh HH, Law PY. Ability of delta-opioid receptors to interact with multiple G-proteins is independent of receptor density. J Biol Chem 1994; 269: 21293-302.
84. Costa T, Herz A. Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 1989; 86: 7321-25.
85. Mullaney I, Carr IC, Milligan G. Analysis of inverse agonism at the δ opioid receptor after expression in Rat-1 fibroblasts. Biochem J 1996; 315: 227-34.
86. Schutz W, Freissmuth M. Reverse intrinsic activity of antagonists on G protein coupled receptors. Trends Pharmacol Sci 1992; 13: 376-80.
87. Lefkowitz RJ, Cotecchia S, Samama P, Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 1993; 14: 303-307.
88. Milligan G, Bond RA, Lee M. Inverse agonism: pharmacological curiosity or potential therapeutic strategy. Trends Pharmacol Sci 1995; 16: 10-13.
89. Law PY, Loh HH. Second messengers in the transduction of multiple opioid receptors' signals. In: Watson RR ed. Drugs of abuse and neurobiology. Boca Raton, FL: CRC Press, 1992: 39-68.
90. Tsu RC, Chan JSC, Wong YH. Regulation of multiple effectors by the cloned δ-opioid receptor: stimulation of phospholipase C and type II adenylyl cyclase. J Neurochem 1995; 64: 2700-707.
91. 35S]GTPγS binding: a tool to evaluate functional activity of a cloned opioid receptor transiently expressed in COS cells. Neurochem Res 1996; 21: 1301-307.
92. Merkouris M, Dragatsis I, Megaritis G et al. Identification of the critical domains of the δ-opioid receptor involved in G protein coupling using site-specific synthetic peptides. Mol Pharmacol 1996; 50: 985-93.
93. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of β-adrenergic receptor function. FASEB J 1990; 4: 2881-89.
94. Collins S, Caron MG, Lefkowitz RJ. Regulation of adrenergic receptor responsiveness through modulation of receptor gene expression. Annu Rev Physiol 1991; 53: 497-508.
95. Way EL. Opioid tolerance-physical dependence-relationship. In: Herz A ed. Opioids II. (Handbook of experimental pharmacology, vol. 104/II.) Berlin: Springer-Verlag, 1993: 573-96.
96. Schulz R. Opioid tolerance dependence in isolated organs. In: Herz A ed. Opioids II. (Handbook of experimental pharmacology, vol. 104/II.) Berlin: Springer-Verlag, 1993: 597-608.
97. Pei G, Kieffer BL, Lefkowitz RJ, Freedman NJ. Agonist-dependent phosphorylation of the mouse delta-opioid receptor: involvement of G protein-coupled receptor kinases but not protein kinase C. Mol Pharmacol 1995; 48: 173-77.
98. Ueda H, Miyamae T, Hayashi C et al. Protein kinase C involvement in homologous desensitization of δ-opioid receptor coupled to Gi1-phospholipase C activation in Xenopus oocytes. J Neurosci 1995; 15: 7485-99.
99. + channel. J Biol Chem 1994; 269: 7839-42.
100. Zhang L, Yu Y, Mackin S, Weight FF, Uhl GR, Wang JB. Differential μ opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters. J Biol Chem 1996; 271: 11449-54.
101. Raynor K, Kong HY, Hines J et al. Molecular mechanisms of agonist-induced desensitization of the cloned mouse kappa opioid receptor. J Pharmacol Exp Ther 1994; 270: 1381-86.
102. Keith DE, Murray SR, Zaki PA et al. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 1996; 277: 19021-24.
103. Trapaidze N, Keith DE, Cvejic S, Evans CJ, Devi LA. Sequestration of the δ opioid receptor: role of the C terminus in agonist-mediated internalization. J Biol Chem 1996; 271: 29279-85.
104. Arden JR, Segredo V, Wang Z, Lameh J, Sadée W. Phosphorylation and agonist specific intracellular trafficking of an epitope-tagged μ-opioid receptor expressed in HEK 293 cells. J Neurochem 1995; 65: 1636-45.
105. Barak LS, Tiberi M, Freedman NJ, Kwatra MM, Lefkowitz RJ, Caron MG. A highly conserved tyrosine residue in G protein-coupled receptors is required for agonist-mediated β2-adrenergic receptor sequestration. J Biol Chem 1994; 269: 2790-95.
106. Malatynska E, Wang Y, Knapp RJ et al. Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80. J Pharmacol Exp Ther 1996; 278: 1083-89.
107. Cvejic S, Trapaidze N, Cyr C, Devi LA. Thr353, located within the COOH-terminal tail of the δ opiate receptor, is involved in receptor down-regulation. J Biol Chem 1996; 271: 4073-76.
108. Law PY, Hom DS, Loh HH. Down regulation of opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells. J Biol Chem 1984; 259: 4096-101.
109. Blanchard SG, Chang K-J, Cuatrecasas P. Characterization of the association of tritiated enkephalin with neuroblastoma cells under conditions optimal for receptor down-regulation. J Biol Chem 1983; 258: 1092-97.